Cargando…
Criteria for indication and treatment modification in a cohort of patients with prostate cancer treated with hormone therapy
BACKGROUND: No published studies have specifically assessed whether treatment modifications to androgen deprivation therapy (ADT) for prostate cancer (PCa) are frequently carried out in routine clinical practice. The current study was conducted to determine what proportion of patients who had initia...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295785/ https://www.ncbi.nlm.nih.gov/pubmed/30574196 http://dx.doi.org/10.1177/1756287218808496 |
_version_ | 1783380927304433664 |
---|---|
author | Lebret, Thierry Ruffion, Alain Latorzeff, Igor Zerbib, Marc Moreau, Jean-Luc Rossi, Dominique Pello-Leprince-Ringuet, Nathalie Perrot, Valérie Hennequin, Christophe |
author_facet | Lebret, Thierry Ruffion, Alain Latorzeff, Igor Zerbib, Marc Moreau, Jean-Luc Rossi, Dominique Pello-Leprince-Ringuet, Nathalie Perrot, Valérie Hennequin, Christophe |
author_sort | Lebret, Thierry |
collection | PubMed |
description | BACKGROUND: No published studies have specifically assessed whether treatment modifications to androgen deprivation therapy (ADT) for prostate cancer (PCa) are frequently carried out in routine clinical practice. The current study was conducted to determine what proportion of patients who had initiated hormone therapy with a gonadotropin-releasing hormone (GnRH) analogue then had their treatment regimen modified during the first 24 months. METHODS: A prospective, noninterventional study was carried out in routine clinical practice in France. Patients with locally advanced or metastatic PCa were followed up for 2 years after treatment initiation with a GnRH analogue. The primary endpoint was the proportion of patients with a modification to their initial hormone therapy. RESULTS: In total, 1301 patients were enrolled into the study by 204 physicians, and the primary endpoint could be evaluated for 891 patients. The GnRH analogue treatment was initiated for metastatic PCa (24.2%), locally advanced PCa without planned local treatment (20.6%), locally advanced PCa in association with radiotherapy (31.6%), and biochemical recurrence after local treatment (21.4%). Hormonal treatment was modified in 43.8% (390/891) of patients during the 24-month follow-up period after GnRH analogue initiation. In 61.3% of cases (239/390), the type of modification involved a change of GnRH analogue formulation or switch to another GnRH analogue. A total of five significant predictive factors for GnRH analogue treatment modification were identified: metastatic stage; physician sector; physician speciality; presence or absence of urinary symptoms; and intermittent versus continuous ADT. CONCLUSIONS: This study shows that in 43.8% of the patients with advanced PCa, ADT is modified in the first 2 years after initiation in routine clinical practice. Predictive factors for alteration of ADT were metastatic stage and the choice of an intermittent schedule. |
format | Online Article Text |
id | pubmed-6295785 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-62957852018-12-20 Criteria for indication and treatment modification in a cohort of patients with prostate cancer treated with hormone therapy Lebret, Thierry Ruffion, Alain Latorzeff, Igor Zerbib, Marc Moreau, Jean-Luc Rossi, Dominique Pello-Leprince-Ringuet, Nathalie Perrot, Valérie Hennequin, Christophe Ther Adv Urol Original Research BACKGROUND: No published studies have specifically assessed whether treatment modifications to androgen deprivation therapy (ADT) for prostate cancer (PCa) are frequently carried out in routine clinical practice. The current study was conducted to determine what proportion of patients who had initiated hormone therapy with a gonadotropin-releasing hormone (GnRH) analogue then had their treatment regimen modified during the first 24 months. METHODS: A prospective, noninterventional study was carried out in routine clinical practice in France. Patients with locally advanced or metastatic PCa were followed up for 2 years after treatment initiation with a GnRH analogue. The primary endpoint was the proportion of patients with a modification to their initial hormone therapy. RESULTS: In total, 1301 patients were enrolled into the study by 204 physicians, and the primary endpoint could be evaluated for 891 patients. The GnRH analogue treatment was initiated for metastatic PCa (24.2%), locally advanced PCa without planned local treatment (20.6%), locally advanced PCa in association with radiotherapy (31.6%), and biochemical recurrence after local treatment (21.4%). Hormonal treatment was modified in 43.8% (390/891) of patients during the 24-month follow-up period after GnRH analogue initiation. In 61.3% of cases (239/390), the type of modification involved a change of GnRH analogue formulation or switch to another GnRH analogue. A total of five significant predictive factors for GnRH analogue treatment modification were identified: metastatic stage; physician sector; physician speciality; presence or absence of urinary symptoms; and intermittent versus continuous ADT. CONCLUSIONS: This study shows that in 43.8% of the patients with advanced PCa, ADT is modified in the first 2 years after initiation in routine clinical practice. Predictive factors for alteration of ADT were metastatic stage and the choice of an intermittent schedule. SAGE Publications 2018-10-24 /pmc/articles/PMC6295785/ /pubmed/30574196 http://dx.doi.org/10.1177/1756287218808496 Text en © The Author(s), 2018 http://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution 4.0 License (http://www.creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Lebret, Thierry Ruffion, Alain Latorzeff, Igor Zerbib, Marc Moreau, Jean-Luc Rossi, Dominique Pello-Leprince-Ringuet, Nathalie Perrot, Valérie Hennequin, Christophe Criteria for indication and treatment modification in a cohort of patients with prostate cancer treated with hormone therapy |
title | Criteria for indication and treatment modification in a cohort of patients with prostate cancer treated with hormone therapy |
title_full | Criteria for indication and treatment modification in a cohort of patients with prostate cancer treated with hormone therapy |
title_fullStr | Criteria for indication and treatment modification in a cohort of patients with prostate cancer treated with hormone therapy |
title_full_unstemmed | Criteria for indication and treatment modification in a cohort of patients with prostate cancer treated with hormone therapy |
title_short | Criteria for indication and treatment modification in a cohort of patients with prostate cancer treated with hormone therapy |
title_sort | criteria for indication and treatment modification in a cohort of patients with prostate cancer treated with hormone therapy |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295785/ https://www.ncbi.nlm.nih.gov/pubmed/30574196 http://dx.doi.org/10.1177/1756287218808496 |
work_keys_str_mv | AT lebretthierry criteriaforindicationandtreatmentmodificationinacohortofpatientswithprostatecancertreatedwithhormonetherapy AT ruffionalain criteriaforindicationandtreatmentmodificationinacohortofpatientswithprostatecancertreatedwithhormonetherapy AT latorzeffigor criteriaforindicationandtreatmentmodificationinacohortofpatientswithprostatecancertreatedwithhormonetherapy AT zerbibmarc criteriaforindicationandtreatmentmodificationinacohortofpatientswithprostatecancertreatedwithhormonetherapy AT moreaujeanluc criteriaforindicationandtreatmentmodificationinacohortofpatientswithprostatecancertreatedwithhormonetherapy AT rossidominique criteriaforindicationandtreatmentmodificationinacohortofpatientswithprostatecancertreatedwithhormonetherapy AT pelloleprinceringuetnathalie criteriaforindicationandtreatmentmodificationinacohortofpatientswithprostatecancertreatedwithhormonetherapy AT perrotvalerie criteriaforindicationandtreatmentmodificationinacohortofpatientswithprostatecancertreatedwithhormonetherapy AT hennequinchristophe criteriaforindicationandtreatmentmodificationinacohortofpatientswithprostatecancertreatedwithhormonetherapy |